61P First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study C. Zhou, G. Chen, Y. Huang, J. Zhou, L. Lin,J. Feng, Z-H. Wang, Y. Shu, J. Shi, Y. Hu, Q-M. Wang,Y. Cheng, F. Wu, J. Chen, X. Lin, Y. Wang, J. Huang, J. Cui, Z. Wang,X. MaESMO Open（2024）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
